Immunotherapy plus chemo aims to shrink stomach tumors before surgery
NCT ID NCT07522151
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) works better than chemo alone for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 874 participants will receive the treatment or a placebo before and after surgery. The study measures how long patients live without cancer returning and how well the tumor responds to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) plus S-1 and oxaliplatin (chemotherapy)
What this could lead to
If successful, this combination could become a new standard treatment to reduce cancer recurrence and improve survival for people with resectable gastric cancer.
What could go wrong
This is a large phase 3 trial, but immunotherapy can cause immune-related side effects. The benefit over standard chemo alone is not yet proven, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 10000, China
Contact
Contact